- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Termination signal.
Displaying page 1 of 1.
EudraCT Number: 2004-004701-23 | Sponsor Protocol Number: 2104-03 | Start Date*: 2005-03-14 |
Sponsor Name:Epix Pharmaceuticals, Inc. | ||
Full Title: Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambers | ||
Medical condition: Detection of thrombi in the arterial vasculature and cardiac chambers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023830-22 | Sponsor Protocol Number: AAG-G-H-1102 | Start Date*: 2012-05-23 | |||||||||||
Sponsor Name:TETEC AG | |||||||||||||
Full Title: NDisc Study: A Prospective Randomized Multicentre Phase I / II Clinical Trial to Evaluate Safety and Efficacy of NOVOCART® Disc plus Autologous Disc Chondrocyte Transplantation (ADCT) in the Treatm... | |||||||||||||
Medical condition: The subject has a disc herniation with back and /or leg pain (radicular pain) and an identification for sequestrectomy according to the guidelines of DGNC and DGOOC. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000004-42 | Sponsor Protocol Number: C0993 | Start Date*: 2019-01-16 | |||||||||||
Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | |||||||||||||
Full Title: TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC | |||||||||||||
Medical condition: Intermediate stage Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005333-21 | Sponsor Protocol Number: CACZ885X2202 | Start Date*: 2015-06-30 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis | |||||||||||||
Medical condition: Pulmonary sarcoidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001262-28 | Sponsor Protocol Number: MSC-TENDO-2015 | Start Date*: 2017-08-21 | |||||||||||
Sponsor Name:Institut de Terapia Regenerativa Tissular S.L. (ITRT) | |||||||||||||
Full Title: Treatment of Refractory Patellar Tendinopathy with MSV *. Comparative study with P-PRP *MSV are bone marrow autologous mesenchymal stem cells, selected and cultured under Good manufacturing Practic... | |||||||||||||
Medical condition: Patients diagnosed with patellar tendinopathy with a minimum of 4 months evolution and have presented two acute episodes, refractory to standard treatments present a gap equal or greater than 3 mm ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004568-72 | Sponsor Protocol Number: ASTX029-01 | Start Date*: 2021-05-27 | ||||||||||||||||||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors | ||||||||||||||||||||||||||||
Medical condition: Advanced Solid Tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000674-73 | Sponsor Protocol Number: LJP 394-90-14 | Start Date*: 2006-08-11 | |||||||||||
Sponsor Name:La Jolla Pharmaceutical Company | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN SYSTEMIC LUPUS ERYTHEMATOS... | |||||||||||||
Medical condition: Systemic lupus erythematosus patients with a history of renal disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003913-21 | Sponsor Protocol Number: NL78575.018.21 | Start Date*: 2022-07-20 | ||||||||||||||||||||||||||
Sponsor Name:Amsterdam UMC | ||||||||||||||||||||||||||||
Full Title: A Prospective, Open-label Pilot Study to Evaluate Effector mechanisms of Hyperbaric Oxygen Therapy in Patients with Moderate-to-Severe Ulcerative Colitis: The PARADOX study | ||||||||||||||||||||||||||||
Medical condition: Ulcerative colitis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004757-88 | Sponsor Protocol Number: PACE-LUNG | Start Date*: 2021-09-22 | ||||||||||||||||
Sponsor Name:Goethe-Universität, vertreten durch den Präsidenten, dieser vertreten durch den LKP (bevollmächtigt durch den Sponsor) | ||||||||||||||||||
Full Title: Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment | ||||||||||||||||||
Medical condition: Advanced NSCLC with common EGFR-Mutation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004643-80 | Sponsor Protocol Number: DS1062-A-U301 | Start Date*: 2021-03-10 | |||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||
Full Title: Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations | |||||||||||||
Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) HU (Completed) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) CZ (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002774-27 | Sponsor Protocol Number: DS1062-A-U202 | Start Date*: 2021-04-16 | |||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||
Full Title: Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed on or After Applicable Targeted Therapy an... | |||||||||||||
Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Trial now transitioned) HU (Completed) NL (Trial now transitioned) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002092-25 | Sponsor Protocol Number: 9766 | Start Date*: 2018-06-18 |
Sponsor Name:University Hospital of Montpellier | ||
Full Title: A phase 2/3 prospective, multicentre randomized, double-blind trial, comparing intra-discal allogeneic adult BM-MSC therapy and sham-treated controls in subjects with chronic low back pain due to l... | ||
Medical condition: Degenerative Disc Disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) FR (Completed) DE (Trial now transitioned) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002535-28 | Sponsor Protocol Number: R4-RA | Start Date*: 2013-01-21 | |||||||||||
Sponsor Name:Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) | |||||||||||||
Full Title: A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA) | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) BE (Completed) IT (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
